M&A Deal Summary |
|
|---|---|
| Date | 2022-04-19 |
| Target | Checkmate Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Regeneron Pharmaceuticals |
| Sellers(s) | Eight Roads |
| Deal Type | Add-on Acquisition |
| Deal Value | 250M USD |
| Advisor(s) | Centerview Partners (Financial) Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1988 |
| Sector | Life Science |
| Employees | 13,677 |
| Revenue | 13.1B USD (2023) |
Regeneron Pharmaceuticals is a biopharmaceutical company based that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 2 |
| Type (Add-on Acquisition) | 1 of 1 |
| State (Massachusetts) | 1 of 2 |
| Country (United States) | 1 of 2 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-08-09 |
Decibel
Boston, Massachusetts, United States Decibel is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance. It has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies, and expertise in inner ear biology. The company is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Its pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. Decibel was founded in 2013 and is based in Boston, Massachusetts. |
Buy | $109M |
Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.
| DEAL STATS | # |
|---|---|
| Overall | 94 of 97 |
| Sector (Life Science) | 48 of 49 |
| Type (Add-on Acquisition) | 42 of 44 |
| State (Massachusetts) | 25 of 26 |
| Country (United States) | 58 of 60 |
| Year (2022) | 2 of 2 |
| Size (of disclosed) | 11 of 19 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-12 |
Noogata
New York, New York, United States Noogata provides no-code artificial intelligence (AI) for enterprises. Its AI platform is built for business users who need to turn their data into actionable insights quickly and easily to drive opportunities, growth, and profit. Noogata delivers the benefits of best-in-class AI for maximum business impact without the complexity and costs of having to develop or maintain your own models. Noogata was founded in 2019 and is based in New York City. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-27 |
Reveal
Paris, France Reveal is the free platform for Partnership, Marketing, and Sales teams to generate revenue through their ecosystem. Reveal is based in Paris, France. |
Buy | - |
